Cheap Drugs Threaten Pharma Giants
This is a India news story, published by Yahoo Finance, that relates primarily to Novo Nordisk news.
India news
For more India news, you can click here:
more India newsNovo Nordisk news
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster Ozempic diabetes treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest patented semaglutide ingredient news, diabetes drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Paraguay medicinesReuters
•In weight loss battle, Novo and Lilly face growing offensive from licensed copies
80% Informative
Novo Nordisk and Eli Lilly expanding sales of popular diabetes and weight-loss drugs.
Cheap copies of their patented remedies are winning approval from some regulators overseas.
The growing number of licenced copies could depress prices for anti-obesity medicines and risk a spillover effect into important markets such as India .
A month 's supply of Semavic , used for diabetes and containing semaglutide, costs 4,420.20 Russian rubles ($ 42.76 ) in Russia .
Ozempic, Wegovy , and Rybelsus have not launched in Bangladesh , a Novo spokesperson told Reuters .
VR Score
91
Informative language
98
Neutral language
46
Article tone
formal
Language
English
Language complexity
73
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links